Anzeige
Mehr »
Samstag, 28.02.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCWK | ISIN: BE0974358906 | Ticker-Symbol: 5YI
Stuttgart
27.02.26 | 21:55
3,545 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
NYXOAH SA Chart 1 Jahr
5-Tage-Chart
NYXOAH SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,3153,80011:18

Aktuelle News zur NYXOAH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrNyxoah: Publication relating to transparency notifications5
MiNyxoah: Information on the total number of voting rights and shares4
18.02.Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East5
NYXOAH Aktie jetzt für 0€ handeln
30.01.Nyxoah SA - 6-K, Report of foreign issuer8
21.01.Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth373Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Mont-Saint-Guibert, Belgium - January 21, 2026, 10:05 pm CET / 4:05 pm ET - Nyxoah SA (Euronext...
► Artikel lesen
14.01.Nyxoah SA - 6-K, Report of foreign issuer1
13.01.Stifel reiterates Buy rating on Nyxoah stock, maintains $12 price target2
13.01.After-Hours Biotech Rally: FBLG, NYXH, FBIO, RVTY, OPCH, ATNM, DSGN Climb On Earnings And Momentum703BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Several biotech and healthcare names posted notable gains in Monday's after-hours trading session, with moves driven by earnings updates, guidance announcements...
► Artikel lesen
12.01.Nyxoah reports Preliminary Q4 results5
12.01.Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026191INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Strong Start in First...
► Artikel lesen
12.01.Nyxoah: Publication relating to transparency notification3
19.12.25Nyxoah Announces Issuance of First Tranche of Convertible Bonds6
19.12.25Nyxoah SA - 6-K, Report of foreign issuer-
17.12.25Nyxoah Announces Commercial Launch of Genio Breakthrough Therapy in the Netherlands571Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the NetherlandsFirst Genio implants successfully performed at OLVG West and Zuyderland hospitals Mont-Saint-Guibert, Belgium -...
► Artikel lesen
05.12.25Nyxoah SA - 6-K, Report of foreign issuer1
02.12.25Nyxoah: Publication relating to transparency notifications1
01.12.25Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System10
26.11.25Nyxoah earns Medicare reimbursement for sleep apnea neuromod3
26.11.25Nyxoah's Genio therapy gets significant 2026 Medicare reimbursement increases under final CMS rule2
26.11.25Nyxoah's Genio Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule277Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah's U.S. commercial rollout...
► Artikel lesen
Weiter >>
70 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1